ABSTRACT Retinoic acid (RA) is a positive regulator of P19 EC cell differentiation. Pre-B cell leukemia transcription factors (PBXs) act in conjunction with homeobox genes during cell differentiation. PBX mRNA and protein levels are increased rapidly in P19 cells during RA-induced differentiation. However, silencing of PBX expression in P19 cells (AS cells) results in a failure of these cells to differentiate upon RA treatment. Chicken Ovalbumin Upstream Promoter Transcription Factor I (COUP-TFI) and Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) are orphan members of the steroid-thyroid hormone superfamily. The mRNA and protein levels of both COUP-TFI and COUP-TFII are low in proliferating wild type P19 EC cells. However, when wild type P19 cells are induced to differentiate upon RA treatment, COUP-TFI and COUP-TFII mRNA and protein levels are dramatically increased while the levels of pluripotency associated gene products are strikingly reduced. Conversely, COUP-TFI and COUP-TFII mRNA levels fail to be elevated upon RA treatment in PBX AS P19 EC cells. Therefore it was hypothesized that COUP-TFs may be downstream targets of PBX and required factors mediating the RA-dependent differentiation cascade in P19 cells. To determine the role of COUP-TFI during differentiation of P19 cells, PBX AS cells that inducibly express V5 tagged COUP-TFI using the Tet-Off® Advanced Inducible Gene Expression system were prepared. Using this system, we demonstrate that exogenous COUP-TFI expression, in a dose-dependent fashion, leads to growth inhibition, modest cell cycle disruption and early apoptosis. Furthermore, using this cell model which inherently is incapable of undergoing RA-mediated differentiation due to blockage of PBX induction, we demonstrate that a supraphysiological level of COUP-TFI expression can overcome the blockage of RA-dependent differentiation in PBX AS cells. However, AS cells expressing a physiological level of COUP-TFI differentiate to endodermal cells only upon treatment with RA. Additionally, gene expression studies indicate that the reductions of pluripotency maintenance genes observed in the COUP-TFI expressing cells are similar to that of wild type P19 cells (upon RA treatment) suggesting that COUP-TFI expression is a driving force towards loss of pluripotency. Moreover, gene expression studies indicate COUP-TFI is involved in the regulatory modulation of at least two RA response genes, CYP26A1 and HoxA1, indicating that COUP-TFI may have some effect on either maintaining or reducing these genes expression levels when COUP-TFI becomes expressed. COUP-TFII is expressed as two distinct variants, Variant 1(V1) and Variant 2 (V2). V1 is the variant that functions as a classical nuclear receptor by binding target DNA sequences and affecting gene transcription whereas V2 is a truncated form of V1 lacking the ability to bind DNA. We therefore hypothesized that V2 could serve as a dominant negative receptor by limiting the amount of functional V1 in the cell. Unexpectedly, we found using P19 cells that overexpress V2 that RA-mediated differentiation proceeded normally suggesting V2 does not function as a dominant negative repressor. Taken together, these studies demonstrate for the first time (i) that COUP-TFI functions as a physiologically relevant regulator during RA-mediated endodermal differentiation of P19 cells and (ii) COUP-TFII V2 is endogenously expressed in P19 cells; however its role during RA-mediated differentiation remains unclear. / Biochemistry

O melanoma é uma forma de câncer com alto índice de morte devido, em parte, à sua tendência de formar metástases. Esse tipo tumoral apresenta deleção de CDKN2A e amplificação de HDM2 em aproximadamente 50 % dos casos, mas apenas 10 % apresentam mutação em p53. Aproveitando-se do fato de a maioria dos casos de melanoma retêm p53 selvagem, uma proteína supressora tumoral e fator de transcrição, utilizamos vetores adenovirais nos quais a expressão dos transgenes é controlada pelo p53 endógeno. Estes vetores foram aperfeiçoados com a inclusão de uma modificação na proteína fibra que permite a eficiente transdução de um amplo espectro de células. Utilizando estes vetores, nosso laboratório mostrou que o tratamento combinado, mas não individual, de vetores virais codificando p19Arf e IFNbeta (interferon-beta) induziu elevados níveis de morte em células de melanoma de camundongo, B16F10. Assim, iniciamos novos estudos que têm como alvo explorar os mecanismos de morte celular e identificar genes críticos cuja expressão é alterada frente o tratamento combinado e que agem como mediadores da resposta celular para a estratégia de transferência gênica. Com este projeto, transferimos a combinação gênica (p19Arf + IFNbeta) para células B16F10 e analisamos o tipo de morte celular induzido. Assim, detectamos o aumento da presença de marcadores de morte celular conhecidos, tais como de apoptose (atividade de caspases e exposição de fosfatidilserina) e de necroptose (expressão de RIPK3 e TNFR1), e a diminuição de um marcador de autofagia (expressão de LC3-II). Além disso, mostramos que a detecção dos três marcadores clássicos de morte imunogênica (ATP, calreticulina e HMGB1) foi possível somente quando as células B16F10 foram tratadas com a combinacao de p19Arf + IFNbeta. Por fim, a avaliação do perfil de expressão gênica através de microarray de cDNA das células B16F10 tratadas com p19Arf + IFNbeta revelou expressão diferenciada de 1054 genes em comparação com células que receberam apenas somente um ou outro transgene. Em seguida, a expressão dos genes Nr3c1, RanBP9, Sin3A, Wdr46, FoxO1, Phlda3 e tp73 foi validada por qPCR e estudos funcionais foram iniciados para revelar a participação destes na resposta celular. Dessa forma, desvendamos importantes aspectos da resposta de células B16F10 frente ao tratamento com p19Arf e IFNbeta / Melanoma is a form of cancer with a high death rate due, in part, to its tendency to generate metastasis. These tumors carry deletion of CDKN2A and amplification of HDM2 in nearly 50 % of cases, but only 10 % have mutations in p53. Taking advantage of the fact that most melanoma cases retain wild type p53, a transcription factor and tumor suppressor protein, we used adenoviral vectors in which transgene expression is controlled by endogenous p53. These vectors were improved with a modification of the fiber protein that allows efficient transduction of a broad spectrum of cells. Using these vectors, our laboratory showed that the combined treatment with viral vectors encoding p19Arf and IFNbeta (interferon-beta) induced high levels of B16F10 (mouse melanoma) cell death, but not when treated with these vectors individually. Thus, we initiated studies to explore the mechanisms of cell death and to identify critical genes involved in the response of B16F10 cells to treatment with p19Arf + IFNbeta. Here, we transferred p19Arf + IFNbeta genes to B16F10 cells and analyzed the type of cell death induced. In this regard, we detected an increase of cell death markers, such as apoptosis (caspase activity and exposure of phosphatidylserine) and necroptosis (RIPK3 and TNFR1 expression) and a decrease of an autophagy marker (LC3-II expression). Furthermore, we showed that the detection of three classic immunogenic cell death markers (ATP, calreticulin and HMGB1) was possible only when B16F10 cells were treated with p19Arf + IFNbeta combination. Lastly, assessment of gene expression profile using cDNA microarray analysis of B16F10 cells treated with p19Arf + IFNbeta revealed differential expression of 1054 genes compared to cells that received only one of the transgenes. Expression of Nr3c1, RanBP9, Sin3a, Wdr46, FoxO1, Phlda3 and TP73 genes was validated by qPCR and functional studies were started to reveal participation of these genes in the cellular response. Thus, we exposed important aspects of the B16F10 cellular response to treatment with p19Arf and IFNbeta

O melanoma é uma forma de câncer com alto índice de morte devido, em parte, à sua tendência de formar metástases. Esse tipo tumoral apresenta deleção de CDKN2A e amplificação de HDM2 em aproximadamente 50 % dos casos, mas apenas 10 % apresentam mutação em p53. Aproveitando-se do fato de a maioria dos casos de melanoma retêm p53 selvagem, uma proteína supressora tumoral e fator de transcrição, utilizamos vetores adenovirais nos quais a expressão dos transgenes é controlada pelo p53 endógeno. Estes vetores foram aperfeiçoados com a inclusão de uma modificação na proteína fibra que permite a eficiente transdução de um amplo espectro de células. Utilizando estes vetores, nosso laboratório mostrou que o tratamento combinado, mas não individual, de vetores virais codificando p19Arf e IFNbeta (interferon-beta) induziu elevados níveis de morte em células de melanoma de camundongo, B16F10. Assim, iniciamos novos estudos que têm como alvo explorar os mecanismos de morte celular e identificar genes críticos cuja expressão é alterada frente o tratamento combinado e que agem como mediadores da resposta celular para a estratégia de transferência gênica. Com este projeto, transferimos a combinação gênica (p19Arf + IFNbeta) para células B16F10 e analisamos o tipo de morte celular induzido. Assim, detectamos o aumento da presença de marcadores de morte celular conhecidos, tais como de apoptose (atividade de caspases e exposição de fosfatidilserina) e de necroptose (expressão de RIPK3 e TNFR1), e a diminuição de um marcador de autofagia (expressão de LC3-II). Além disso, mostramos que a detecção dos três marcadores clássicos de morte imunogênica (ATP, calreticulina e HMGB1) foi possível somente quando as células B16F10 foram tratadas com a combinacao de p19Arf + IFNbeta. Por fim, a avaliação do perfil de expressão gênica através de microarray de cDNA das células B16F10 tratadas com p19Arf + IFNbeta revelou expressão diferenciada de 1054 genes em comparação com células que receberam apenas somente um ou outro transgene. Em seguida, a expressão dos genes Nr3c1, RanBP9, Sin3A, Wdr46, FoxO1, Phlda3 e tp73 foi validada por qPCR e estudos funcionais foram iniciados para revelar a participação destes na resposta celular. Dessa forma, desvendamos importantes aspectos da resposta de células B16F10 frente ao tratamento com p19Arf e IFNbeta / Melanoma is a form of cancer with a high death rate due, in part, to its tendency to generate metastasis. These tumors carry deletion of CDKN2A and amplification of HDM2 in nearly 50 % of cases, but only 10 % have mutations in p53. Taking advantage of the fact that most melanoma cases retain wild type p53, a transcription factor and tumor suppressor protein, we used adenoviral vectors in which transgene expression is controlled by endogenous p53. These vectors were improved with a modification of the fiber protein that allows efficient transduction of a broad spectrum of cells. Using these vectors, our laboratory showed that the combined treatment with viral vectors encoding p19Arf and IFNbeta (interferon-beta) induced high levels of B16F10 (mouse melanoma) cell death, but not when treated with these vectors individually. Thus, we initiated studies to explore the mechanisms of cell death and to identify critical genes involved in the response of B16F10 cells to treatment with p19Arf + IFNbeta. Here, we transferred p19Arf + IFNbeta genes to B16F10 cells and analyzed the type of cell death induced. In this regard, we detected an increase of cell death markers, such as apoptosis (caspase activity and exposure of phosphatidylserine) and necroptosis (RIPK3 and TNFR1 expression) and a decrease of an autophagy marker (LC3-II expression). Furthermore, we showed that the detection of three classic immunogenic cell death markers (ATP, calreticulin and HMGB1) was possible only when B16F10 cells were treated with p19Arf + IFNbeta combination. Lastly, assessment of gene expression profile using cDNA microarray analysis of B16F10 cells treated with p19Arf + IFNbeta revealed differential expression of 1054 genes compared to cells that received only one of the transgenes. Expression of Nr3c1, RanBP9, Sin3a, Wdr46, FoxO1, Phlda3 and TP73 genes was validated by qPCR and functional studies were started to reveal participation of these genes in the cellular response. Thus, we exposed important aspects of the B16F10 cellular response to treatment with p19Arf and IFNbeta

Les plantes, comme tous les êtres vivants, subissent les assauts de différents agents pathogènes. Elles doivent donc entre autres se protéger des microbes et, pour ce faire, déploient deux mécanismes immunitaires actifs : la reconnaissance des éliciteurs et l’interférence à l’ARN (ARNi). Dans le cadre de la reconnaissance des éliciteurs, il y a premièrement l’immunité induite par les PAMP (PTI). Cette immunité de faible envergure permet à la plante de se protéger de la plupart des microbes indésirables. Afin de surpasser cette PTI, un pathogène bien outillé pour infecter une plante déploie des facteurs de virulence nommés effecteurs. Dans ce cas, pour se défendre, la plante devra arborer un gène de résistance dominant qui produira une protéine de résistance. Cette protéine reconnaitra de manière spécifique l’effecteur du pathogène et mettra en place une réponse de défense hautement efficace, l’immunité induite par un effecteur (ETI). Le deuxième mécanisme immunitaire, l’ARNi, est un mécanisme principalement antiviral qui permet à la plante de cibler les génomes viraux de manière séquence spécifique. À l’image de la PTI, les virus ont évolué afin de contourner l’ARNi en produisant des protéines spécialisées qui altèrent le fonctionnement de l’ARNi. C’est ce que l’on nomme des suppresseurs viraux de l’ARNi ou VSR. J’ai démontré durant ma thèse que la protéine P19, un VSR qui séquestre les petits ARN (siARN), était reconnue chez certains cultivars de tabac. Cette reconnaissance induit une réponse de type ETI. Cette réponse, nécessitant l’action conjointe de l’acide salicylique et de l’éthylène, est caractérisée par la production de protéines reliées à la pathogénèse et par la mise en place d’une réaction hypersensible. Cette réponse de défense est si efficace que, dans le cadre d’une infection virale, il n’y a pas de lésion macroscopique et microscopique. Cette situation se nomme la résistance extrême. Qui plus est, cette réponse de défense nécessite la capacité de liaison de la P19 à un petit ARN. Mes travaux ont aussi démontré l’implication de certaines protéines clés de la machinerie de l’ARNi dans la mise en place de la réponse de défense contre les VSR. La plante pourrait donc percevoir les dommages causés par les VSR à la machinerie de l’ARNi via des protéines clés de ce mécanisme. Ces recherches à terme permettrons de mieux documenter le système immunitaire des plantes, ce qui permettra par la ii suite de mieux sélectionner les cultivars mis en culture et de diminuer l’impact des pathogènes sur les cultures tout en réduisant l’utilisation des pesticides.

The role of endogenous molecules in facilitating stem cell differentiation into cardiomyocytes is yet to be fully understood. SPC and S1P, common biolipids, promote cardiac differentiation of mesenchymal stem cells and cardiac progenitor cells, however, the same potential of closely related lysophosphatidic acid (LPA) has only recently become evident. The initial cardio-protection offered by elevated LPA levels in response to acute myocardial infarction and the ability of this biolipid to mediate other cellular fates served as a rationale to investigate the ability of LPA to mediate the cardiac differentiation of the murine P19 teratocarcinoma cell line and further examine the role of signalling molecules critical to lineage commitment. All experiments were carried out using P19 stem cells, cultured in supplemented alpha-minimal essential medium. Cells were aggregated into embryoid bodies in the presence of 5µM LPA in non-tissue grade Petri dishes over the course of 4 days to commence the differentiation process. Inhibitors were added 60 minutes before LPA while control cells were cultured in medium only. Embryoid bodies were transferred to 6-well tissue culture grade plates and cultured for a further 6 days. Cardiac differentiation was assessed by examining the expression of ventricular myosin light chain (MLC1v) by western blot and the role of LPA receptors 1-4, PKC, PI3K, MAPKs, and NF-κB were determined by examining the changes in this expression in the presence of selective inhibitors. The induction and regulation of GATA4, MEF2C, ATF-2, JNK, and YAP was also determined by western blotting. The activity and regulation of transcription factors, AP-1 and NF-κB, and the MAPKs was determined using ELISA kits. LPA induced the differentiation of P19 cells into cardiomyocytes most effectively when used at a concentration of 5µM as evidenced by the expression of MLC1v on day 10 of the differentiation process. Inhibition of LPA receptor 4 (0.1mg/mL Suramin), LPA receptors 1/3 (20µM Ki16425), LPA receptor 2 (7.5nM H2L5186303), PKC (10µM BIM-1), PI3K (20µM LY294002), ERK (20µM PD98059), JNK (10µM SP600125), and NF-κB (0.01nM CAY10470) blocked LPA induced expression of MLC1v. GATA4, MEF2C, pcJun, pJunD, and pATF2 expression increased in a time-dependent manner peaking at day 10 in LPA treated cells. GATA4 and pcJun expression was suppressed by all the inhibitors whereas MEF2C expression was unaffected by CAY10470, pJunD expression was unaffected by H2L5186303, pATF2 and NF-κB expression was unaffected by LY294002, but the latter was enhanced by Suramin. JNK was transiently phosphorylated in all cells whereas YAP was dephosphorylated 24-48 hours after EB formation in LPA treated cells and were both affected by Ki16425 and partially by H2L5186303 treatment. In conclusion, the studies carried out in this thesis have shown that LPA mediates the cardiac differentiation of P19 cells through LPA receptor 2, partially through receptors 1/3, and possibly through receptor 4. Conceivably downstream of these receptors, PKC, PI3K, MAPK, and NF-κB signalling pathways converge on the regulation of cardiac-specific transcription factors GATA4 and MEF2C along with ubiquitous transcription factor AP-1. JNK signalling is initiated through LPA receptors 1/3 and partially through receptor 2 to commence the cardiac program however the role of JNK and YAP in the proliferation of aggregating EBs is yet to be entirely established.

Tomato bushy stunt virus (TBSV) provides a good model system to investigate molecular virus-host interactions in plants. P22 and P19 proteins encoded by TBSV contribute to multiple invasion-associated functions. Green fluorescence-mediated visualization of TBSV invasion in this study suggests that virus exit from inoculated epidermal cells is a crucial event. Close examination of one P22 mutant showed that it had lost the capacity to move between epidermis and mesophyll which was possibly due to an altered subcellular localization. P19 is a potent suppressor of RNA interference (RNAi) in various systems by forming dimers that bind 21-nucleotide (nt) duplex siRNAs (short interfering RNAs), to affect the programming of the RNA-induced silencing complex (RISC). P19 is attractive for biotechnological and research purposes to prevent RNAi of certain value-added genes in plants. To obtain a good plant-based expression platform, a suppression-active mutant P19 was expressed in transgenic N. benthamiana lines. This is the first example of P19 accumulating to detectable levels in a transgenic plant and initial results suggest it is actively suppressing RNAi. Furthermore, to investigate the correlation between siRNA binding of P19 and its various biological roles, predicted siRNA-interacting sites of TBSV P19 were modified, and the corresponding TBSV mutants were used to inoculate plants. Substitutions on siRNA-contact sites on the central domain of P19 resulted in more severe symptoms in N. benthamiana compared to those affecting peripheral regions. All tested combinations of siRNA-binding mutations were associated with reduced accumulation of total TBSV-derived siRNAs, and loss of siRNA sequestration by P19. Additionally, some modifications were found to cause RNAi-mediated disappearance of viral and host materials in N. benthamiana but not in spinach. In conclusion, exit out of epidermal cells is a key host range determinant for TBSV and particular amino acids on P22 may influence this by regulating the proper subcellular localization. Mutant P19 transgenic plants were successfully established with minor physiological effects to be applied as a platform to study RNAi and to over-express proteins. Finally, a compromised P19-siRNA binding impacts symptom development, systemic invasion, integrity of virus plus host RNA and proteins, and that all in a hostdependent manner.

Thesis (Ph.D.)--University of Alabama at Birmingham, 2008. / Title from first page of PDF file (viewed on June 24, 2009). Includes bibliographical references (p. 88-101).

No description available.

TBN1 is a nuclease with antitumor activity. The main goal of this work was to estimate how TBN1 and its modificated variants are stable in the ?leaf factory? system used for its production and whether it can be enhanced or influenced by chosen potential ?modificators? i. e. silencing supressors, transcription factors, glycosyltransferases and kinases. Nicotiana benthamina plants were infiltrated with the mixture of Agrobacterium tumefaciens strains bearing the nuclease plant expression vectors and co-infiltrated with the ?modifying? vectors. The nuclease and protein analyses revealed that nuclease TBN1 wt and its modificated variants are stable in the used ?leaf factory? system as to their molecular mass, only quantitative changes were detected. Expreximents showed that activity and production of the nucleases increased upon coinfiltration with silencing supressor and decreased upon coexpression with chosen transcription factor. Glycosyltransferases and kinases influenced activity and production only insignificantly. The experiments also revealed that modificated variants of TBN1 have different molecular weight suggesting that different N-glycosylation domains have different length of sugar chain and influence on nuclear activity. Our data show that this expression in planta seems to be suitable for production for study of antitumor activity of these nucleases.

RNA silencing is a cellular mechanism of post-transcriptional gene regulation which is highly conserved among the plant and animal kingdoms of life, and plays a critical part of developmental biology, maintenance of homeostasis, and host-pathogen interactions. The pathway is engaged by small double-stranded (ds)RNA molecules (small RNAs), which effect sequence specific gene silencing by targeting complementary RNA sequences. There are several classes of small RNAs which engage the pathway. MicroRNAs (miRNAs) are expressed in the genome as endogenous regulators of gene expression. Short-interfering RNAs (siRNAs) are usually from exogenous sources such as viral-derived short-interfering RNAs, or synthetic siRNAs which are applied to cells or organisms to inhibit expression of specific genes. The p19 protein is a viral suppressor of RNA silencing (VSRS) endogenous to tombusviruses, which binds small RNA duplexes of any sequence with extremely high affinity. Because of its unique binding properties, recombinant p19 proteins are an excellent platform for tool development surrounding the RNA silencing pathway and are used extensively in novel applications for modulating the activity of small RNAs in living systems and for detecting small RNAs in biological samples. Herein we present work that has increased the breadth of p19’s utility as a biotechnology tool in three distinct realms. First, we present a chemical biology approach which combines p19 and small molecules for potent inhibition of the RNA silencing pathway in human cells. Secondly, we present the development of a novel fusion protein between p19 and a cell penetrating peptide (CPP), which functions as an siRNA delivery agent to allow gene knockdown in human cells. Thirdly, we have improved the utility of p19 for detecting and sequestering human miRNAs through rationally designing the binding surface; we describe mutations which dramatically enhance p19's affinity for human miRNA-122. The work presented here adds to the growing repertoire of engineered RNA binding proteins (RBPs) as tools for studying small RNA molecules and modulating their activity for applications in human therapeutics.